Compugen (CGEN) Shares Outstanding (Diluted Average) (2009 - 2025)
Compugen's (CGEN) quarterly Shares Outstanding (Diluted Average) came in at $93.5 million in Q3 2025, up 4.14% year-on-year from $89.8 million in Q3 2024, and up 58461503.12% quarter-over-quarter from $160.0 in Q2 2025.
Compugen (CGEN) Shares Outstanding (Diluted Average) (2009 - 2025) Analysis & Trends
Compugen has disclosed Shares Outstanding (Diluted Average) across 15 years of filings, most recently posting $93.5 million for Q3 2025.
- Shares Outstanding (Diluted Average) for Q3 2025 came in at $93.5 million, up 4.14% year-over-year; the trailing twelve-month figure through Sep 2025 was $93.5 million (up 4.14% YoY), and the FY2015 annual result was $50.5 million, up 0.76% from the prior year.
- Shares Outstanding (Diluted Average) came in at $93.5 million for Q3 2025 at Compugen, up from $160.0 in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $93.5 million in Q3 2025 to a low of $100.0 in Q2 2024.
- The 5-year median for Shares Outstanding (Diluted Average) is $43.5 million (2021), against an average of $44.8 million.
- Across the five-year window, Shares Outstanding (Diluted Average) surged 39501600.45% in 2023 and tumbled 100.0% in 2024, its largest moves.
- Compugen's Shares Outstanding (Diluted Average) stood at $230.0 in 2021, then dropped by 4.35% to $220.0 in 2022, then soared by 40140958.64% to $88.3 million in 2023, then increased by 1.71% to $89.8 million in 2024, then grew by 4.14% to $93.5 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $93.5 million (Q3 2025), $160.0 (Q2 2025), and $89.8 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Compugen | 189.59 Mn | 97.83 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 93.54 Mn |
| Jun 30, 2025 | 160.00 |
| Sep 30, 2024 | 89.82 Mn |
| Jun 30, 2024 | 100.00 |
| Sep 30, 2023 | 88.31 Mn |
| Jun 30, 2023 | 86.90 Mn |
| Jun 30, 2022 | 220.00 |
| Jun 30, 2021 | 230.00 |
| Mar 31, 2019 | 60.02 Mn |
| Mar 31, 2018 | 51.98 Mn |
| Mar 31, 2017 | 51.13 Mn |
| Dec 31, 2015 | 50.53 Mn |
| Jun 30, 2015 | 50.41 Mn |
| Dec 31, 2014 | 50.14 Mn |
| Jun 30, 2014 | 49.80 Mn |
| Dec 31, 2013 | 42.74 Mn |
| Sep 30, 2013 | 39.15 Mn |
| Jun 30, 2013 | 39.14 Mn |
| Dec 31, 2012 | 36.25 Mn |
| Sep 30, 2012 | 36.80 Mn |